Blackstone Life Sciences Announces Collaboration to Support Moderna’s Influenza Program
“Moderna has demonstrated a remarkable ability to impact human health through mRNA vaccines targeting respiratory illnesses. This landmark collaboration is another example of our long-standing strategy to partner with the world’s leading life science companies to advance their critical path vaccines, medicines and medical technologies to patients,” said
“Moderna is advancing a broad and diverse pipeline at a pace not seen before in our industry,” said
This new collaboration continues Blackstone Life Sciences’ work and support for many of the world’s leading and most innovative biopharmaceutical and medical technology companies.
About the Transaction
Under the terms of the agreement, funds managed by Blackstone Life Sciences will provide up to
More information about Moderna’s flu program pipeline can be found in Moderna’s Vaccines Day press release – being announced concurrently this morning at: https://investors.modernatx.com/. Additional terms of the agreement were not disclosed.
About Blackstone Life Sciences
Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients’ lives and currently has more than
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327290051/en/
paula.chirhart@blackstone.com
(347) 463-5453
Source: